Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Radiopharm Theranostics / Equity Bottom-Up

<ul>
<li>Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.</li>
<li>Its approach recognizes the opportunities in tumors beyond prostate, thyroid &amp; neuroendocrine targets originated by precision oncology &amp; validated by clinical trials &amp; regulatory approval.</li>
<li>RAD101, an 18F radioisotope imaging brain metastases is the most advanced asset.</li>
</ul>


Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.
Its approach recognizes the opportunities in tumors beyond prostate, thyroid &amp; neuroendocrine targets originated by precision oncology &amp; validated by clinical trials &amp; regulatory approval.
RAD101, an 18F radioisotope imaging brain metastases is the most advanced asset.


RADX: Initiating Coverage - Adding a Radioisotope to Precision Oncology